135 related articles for article (PubMed ID: 21060271)
1. Intravitreal infliximab in patients with macular degeneration who are nonresponders to antivascular endothelial growth factor therapy.
Arias L; Caminal JM; Badia MB; Rubio MJ; Catala J; Pujol O
Retina; 2010; 30(10):1601-8. PubMed ID: 21060271
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study.
Holz FG; Amoaku W; Donate J; Guymer RH; Kellner U; Schlingemann RO; Weichselberger A; Staurenghi G;
Ophthalmology; 2011 Apr; 118(4):663-71. PubMed ID: 21459217
[TBL] [Abstract][Full Text] [Related]
3. A 1-year retrospective review of ranibizumab for naive nonsubfoveal choroidal neovascularization secondary to age-related macular degeneration.
Arias L; Ruiz-Moreno JM; Gómez-Ulla F; Fernández M; Montero J
Retina; 2009; 29(10):1444-9. PubMed ID: 19730163
[TBL] [Abstract][Full Text] [Related]
4. Adverse events after intravitreal infliximab (Remicade).
Giganti M; Beer PM; Lemanski N; Hartman C; Schartman J; Falk N
Retina; 2010 Jan; 30(1):71-80. PubMed ID: 19996827
[TBL] [Abstract][Full Text] [Related]
5. Ranibizumab for choroidal neovascularization secondary to causes other than age-related macular degeneration: a phase I clinical trial.
Heier JS; Brown D; Ciulla T; Abraham P; Bankert JM; Chong S; Daniel PE; Kim IK
Ophthalmology; 2011 Jan; 118(1):111-8. PubMed ID: 20678799
[TBL] [Abstract][Full Text] [Related]
6. Cystoid macular degeneration in exudative age-related macular degeneration.
Querques G; Coscas F; Forte R; Massamba N; Sterkers M; Souied EH
Am J Ophthalmol; 2011 Jul; 152(1):100-107.e2. PubMed ID: 21570056
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of anti-vascular endothelial growth factor (VEGF) therapy with intravitreal ranibizumab (Lucentis) for naive retinal vein occlusion: 1-year follow-up.
Pece A; Isola V; Piermarocchi S; Calori G
Br J Ophthalmol; 2011 Jan; 95(1):56-68. PubMed ID: 20601660
[TBL] [Abstract][Full Text] [Related]
8. Significant improvements in near vision, reading speed, central visual field and related quality of life after ranibizumab treatment of wet age-related macular degeneration.
Frennesson C; Nilsson UL; Peebo BB; Nilsson SE
Acta Ophthalmol; 2010 Jun; 88(4):420-5. PubMed ID: 19678811
[TBL] [Abstract][Full Text] [Related]
9. Role of vascular endothelial growth factor polymorphisms in the treatment success in patients with wet age-related macular degeneration.
Boltz A; Ruiß M; Jonas JB; Tao Y; Rensch F; Weger M; Garhöfer G; Frantal S; El-Shabrawi Y; Schmetterer L
Ophthalmology; 2012 Aug; 119(8):1615-20. PubMed ID: 22521084
[TBL] [Abstract][Full Text] [Related]
10. Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study.
Cohen SY; Mimoun G; Oubraham H; Zourdani A; Malbrel C; Queré S; Schneider V;
Retina; 2013 Mar; 33(3):474-81. PubMed ID: 23266880
[TBL] [Abstract][Full Text] [Related]
11. Monthly ranibizumab for nonproliferative macular telangiectasia type 2: a 12-month prospective study.
Charbel Issa P; Finger RP; Kruse K; Baumüller S; Scholl HP; Holz FG
Am J Ophthalmol; 2011 May; 151(5):876-886.e1. PubMed ID: 21334595
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab in advanced-stage neovascular age-related macular degeneration with visual acuity lower than 20/200.
Parodi MB; Cascavilla M; Papayannis A; Kontadakis DS; Bandello F; Iacono P
Arch Ophthalmol; 2012 Jul; 130(7):934-5. PubMed ID: 22776937
[No Abstract] [Full Text] [Related]
13. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion.
Spaide RF; Chang LK; Klancnik JM; Yannuzzi LA; Sorenson J; Slakter JS; Freund KB; Klein R
Am J Ophthalmol; 2009 Feb; 147(2):298-306. PubMed ID: 18929354
[TBL] [Abstract][Full Text] [Related]
14. Randomized study of bevacizumab vs ranibizumab for age-related macular degeneration: inappropriate conclusions.
Messori A; Fadda V; Trippoli S
Am J Ophthalmol; 2010 May; 149(5):867; author reply 867. PubMed ID: 20399931
[No Abstract] [Full Text] [Related]
15. Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age-related macular degeneration in the 2-year anchor study.
Sadda SR; Stoller G; Boyer DS; Blodi BA; Shapiro H; Ianchulev T
Retina; 2010 Oct; 30(9):1390-9. PubMed ID: 20924261
[TBL] [Abstract][Full Text] [Related]
16. Short-term progression of wet AMD and correlation with 1-year treatment results.
Munk M; Kiss C; Sulzbacher F; Eisenkölbl S; Sacu S; Kalcher K; Jampol L; Schmidt-Erfurth U
Acta Ophthalmol; 2012 Sep; 90(6):e420-7. PubMed ID: 22339794
[TBL] [Abstract][Full Text] [Related]
17. Dosing regimen and the frequency of macular hemorrhages in neovascular age-related macular degeneration treated with ranibizumab.
Barbazetto I; Saroj N; Shapiro H; Wong P; Freund KB
Retina; 2010 Oct; 30(9):1376-85. PubMed ID: 20683380
[TBL] [Abstract][Full Text] [Related]
18. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
Lalwani GA; Rosenfeld PJ; Fung AE; Dubovy SR; Michels S; Feuer W; Davis JL; Flynn HW; Esquiabro M
Am J Ophthalmol; 2009 Jul; 148(1):43-58.e1. PubMed ID: 19376495
[TBL] [Abstract][Full Text] [Related]
19. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.
Tseng JJ; Vance SK; Della Torre KE; Mendonca LS; Cooney MJ; Klancnik JM; Sorenson JA; Freund KB
J Glaucoma; 2012; 21(4):241-7. PubMed ID: 21423038
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial.
Donahue SP; Recchia F; Sternberg P
Am J Ophthalmol; 2010 Aug; 150(2):287; author reply 287. PubMed ID: 20670740
[No Abstract] [Full Text] [Related]
[Next] [New Search]
